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Abstract
Objective: Mesenchymal stem cells (MSC) from various sources have the potentials to positively affect regenerative medicine. 
Furthermore, pre-conditioning strategies with different agents could improve the efficacy of cell therapy. This study compares 
the effects of an anti-inflammatory and antioxidant agent, melatonin, on protection of bone marrow-derived MSCs (BMSCs) 
and adipose tissue-derived MSCs (ADSCs).
Materials and Methods: In this experimental study, rat BMSCs and ADSCs were isolated and expanded. Pre-conditioning 
was performed with 5 µM melatonin for 24 hours. Cell proliferation and viability were detected by MTT assay. Expression of 
BAX, BCL2, melatonin receptors and osteocalcin genes were evaluated by reverse transcriptase-polymerase chain reaction 
(RT-PCR). Also, apoptosis was detected with tunnel assay. Osteogenic differentiation was analyzed using alizarin red staining. 
Results: No significant increase was found in cell viability between BMSCs and ADSCs after melatonin preconditioning. 
Following melatonin preconditioning, BAX expression was significantly down-regulated in both ADSCs and BMSCs 
(P<0.05), with the difference being more significant in ADSCs compared to BMSCs.  BCL2 expression was increased 
significantly in both cell types after preconditioning. Metalothionine 1 and Metalothionine 2 were both upregulated 
significantly in the two cell types (P<0.05). Melatonin increased osteogenesis capability through increasing osteocalcin 
expression. However, expression of osteocalcin in BMSCs before and after preconditioning was higher than that in 
ADSCs. On the other hand, melatonin expression in ADSCs was in higher levels than in BMSCs. Melatonin also 
improved alizarin red concentration significantly in both BMSCs and ADSCs (P<0.05). Alizarin red staining severity 
increased significantly in ADSCs after preconditioning compared to BMSCs (P<0.05).                   
Conclusion: Here we have shown that the effects of preconditioning on melatonin expression in ADSCs are higher than 
those in BMSCs. These findings could be used in adoption of a proper preconditioning protocol based on the sources of MSCs 
in specific clinical applications, especially in bone regeneration.          
Keywords: Apoptosis, Bone Marrow Mesenchymal Stem Cells, Melatonin, Osteogenesis 
Cell Journal(Yakhteh), Vol 20, No 4, Jan-Mar (Winter) 2019, Pages: 450-458
Citation: Rafat A, Mohammadi Roushandeh A, Alizadeh A, Hashemi-Firouzi N, Golipoor Z. Comparison of the melatonin preconditioning efficacy between 
bone marrow and adipose-derived mesenchymal stem cells. Cell J. 2019; 20(4): 450-458. doi: 10.22074/cellj.2019.5507.
Introduction
In the field of cell therapy and regenerative medicine, 
bone marrow and adipose tissue  are considered as two 
main sources of mesenchymal stem cells (MSCs) (1-5).
Bone marrow MSCs (BMSCs) and adipose-derived 
stem cells (ADSCs) present similar properties 
morphologically and in terms of cell surface 
antigens (4, 6). On the other hand, they show some 
significant biological differences like proliferation 
rate, differentiation capacity, cytokine secretome and 
chemokine receptor expression (7). ADSCs represent 
biological advantages in proliferation potentials 
and immunomodulatory effects, while BMSCs 
have advantages in osteogenic and chondrogenic 
differentiation capabilities. Also, in terms of 
differences in secreted proteins, ADSCs produce basic 
fibroblast growth factor, interferon-γ, and insulin-like 
growth factor-1, while BMSCs produce stem cell-
derived factor-1 and hepatocyte growth factor (8).
Finding a safe harvesting protocol with low pain for 
MSC isolation is a challenge in cell therapy. Unlike 
ADSC isolation, BMSC harvest procedure is invasive 
and painful for the patients. In addition to the problems 
associated with cell harvest, the number of isolated 
cells is low from both sources and in vitro expansion of 
the cells is needed prior to transplantation. Therefore, 
they are frequently subjected to oxidative stress and 
other toxic factors within their microenvironment 
that lead to apoptosis during the harvest, expansion 
and transplantation processes (9). It is demonstrated 
that preconditioning with some agents not only can 
reduces oxidative stress and apoptosis, but also can 
increase some desired potentials of MSCs (10, 11). 
Melatonin, a human pineal gland hormone, has anti-
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inflammatory and anti-apoptotic properties (12). It is 
also a powerful free radical scavenger and activator of 
cellular antioxidants in various cell types. In addition, 
melatonin is a safe drug that has been approved by 
FDA with few side effects and its therapeutic effects 
have been proven in several human clinical trials (13).
Evidence suggests that melatonin protects human 
ADSCs from oxidative stress and cell death (9). 
Previous studies have shown that pretreatment 
with melatonin can enhance the homing of BMSCs 
after transplantation (14) and improves therapeutic 
outcomes of BMSCs in the case of transplantation in 
liver  fibrosis (15). Also, it is suggested that melatonin 
may contribute significantly in regulation of osteogenic 
differentiation of MSCs (11).
Although there are strong evidences to show the cyto-
protective effects of melatonin, it is necessary to know 
its behavior after using as a preconditioning agent. 
Therefore, the present study is designed to compare 
preconditioning efficacy of melatonin in BMSCs and 
ADSCs.
Methods and Materials
Study design
The present study was designed as an experimental 
study. The cells were divided into 4 treatment groups. 
BMSCs with or without melatonin treatment, ADSCs with 
or without melatonin treatment. Reverse transcriptase-
polymerase chain reaction (RT-PCR) was performed for 
the 4 treatment groups. 
Isolation and expansion of bone marrow mesenchymal 
stem cells 
All animal studies were approved by the Ethical 
Committee of Hamadan University of Medical Sciences. 
About 6-8 weeks-old male Wistar rats were euthanized 
by diethyl ether and their femurs and tibia were removed 
under sterile conditions. Then, in the long bones proximal 
and distal ends were cut. Bone marrow was obtained 
by flushing of α-Minimum Essential Medium (α-MEM, 
Sigma, USA) containing 1000 U/ml Penicillin through 
the bones using a syringe (22G needle). The collected 
bone marrow was centrifuged at 1000×g for 5 minutes. 
and the pellets were collected. Finally, the harvested 
cells were cultured at a density of 1.0×106 in each T75 
tissue culture flask containing α-MEM with 15% fetal 
bovine serum (Sigma, USA), 100 U/ml penicillin and 
100 µg/ml streptomycin. The medium was refreshed 
every 3 days. Cells were sub-cultured using trypsin/
ethylenediaminetetraacetic acid (EDTA, Sigma, USA) 
when they reached 90% confluency.
Isolation and expansion of adipose tissue-derived 
mesenchymal stem cells 
After euthanizing the rats, the white adipose tissue 
of epididym from each rat was removed in antiseptic 
conditions. The adipose tissue was warmed in 37˚C and 
then washed two times with phosphate-buffered saline 
(PBS, Invitrogen, USA) containing 1% Penicillin/
Streptomycin (Invitrogen, USA). To digest the adipose 
tissue the samples were treated with 0.1% collagenase 
type I (Gibco, USA) and 1% bovine serum albumin 
(BSA, dissolved in warm PBS) (Invitrogen, USA). 
For total digestion and homogenization, the sample 
was submerged in water bath for 30 minutes. Then, 
it was centrifuged at 1200 rpm at room temperature 
for 5 minutes. The supernatant was discarded and the 
pellet was re-suspended in 1% BSA solution and was 
centrifuged again in red blood cell (RBC) lysis buffer 
to remove red blood cells (Kiazist, Iran). Finally, the 
harvested cells were cultured in DMEM/Ham’s F-12 
medium containing 10% Iran. Finally, the harvested 
cells were cultured in DMEM/Ham’s F-12 medium 
containing 10% fetal bovine serum (FBS, Gibco, 
USA) and 1% Penicillin/Streptomycin at 37˚C and 5% 
CO
2
. The medium was changed every 3 days and the 
cells were sub-cultivated using trypsin/EDTA (Sigma, 
USA) at 90% confluency.
Multi-lineage differentiation of BMSCs and ADSCs
Passage 2 cells were cultured in DMED-Low glucose 
for 3 days at a density of 5000 cells/cm2. Then the 
medium was replaced with differentiation media. The 
osteogenic differentiation medium contained αMEM, 
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 
100 mg/ml streptomycin, 10 nM dexamethasone, 50 
mg/ml L-ascorbic acid and 10 mM b-glycerophosphate. 
The adipogenic medium consisted of αMEM, 10% FBS, 
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin, 10 nM dexamethasone, 200 mg/ml 
indomethacin, 5 mg/ml insulin and 0.5 mM IBMX. Each 
of the media were refreshed every 3-4 days. After 21 days, 
osteogenic and adipogenic differentiations were detected 
by alizarin red and oil red O staining, respectively.
Melatonin preconditioning of BMSCs and ADSCs
Passage 5 cells were cultured in T-75 flasks. After 24 
hours, the cells were pretreated with 5µM melatonin 
(Sigma, USA) for 24 hours. The melatonin solution was 
prepared by dissolving it in ethanol at a concentration of 
1.15 µg/ml (14). Then the pretreated cells were washed to 
remove the melatonin solution and were cultured in 96-
well plates at a density of 104 for further experiments. 
Cell viability assay
The 3-(4, 5-Dimethylthiazol- 2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT, Sigma, USA) test represents the mitochondrial 
metabolic activity in cell culture, which indicates the 
number of viable cells. Briefly, the cells were cultivated 
into a 96-well plate at a density of 1.0×106/well. After 
washing with PBS, 100 µl of culture medium containing 
50 µl MTT reagent was added to each well. Following 
incubation in the incubator at 37˚C and 5% CO
2 
for 1 
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hour, 200 µl dimethyl sulfoxide (DMSO) was added to 
the wells and the absorption of the media was measured 
by ELISA Reader at 630 nm.
Reverses transcriptase-polymerase chain reaction
Total RNA was extracted from the cells using 
RNA extraction solution (RNX™, Cinnagen, Iran). 
The quantity and quality of the extracted RNA were 
checked using nanodrop (Thermo Fisher Scientific, 
USA) and electrophoresis, respectively. cDNA was 
synthesized from 5 µg total RNA using a Fermentas kit 
(Fermentas, Canada) according to the manufacturer’s 
manuals. Then, 25 µl of PCR cocktail, containing 0.2 
pM of each primer (forward and reverse) (Table 1), 0.3 
mM dNTP, 1.5 mM MgCl
2
, 1U taq DNA polymerase, 
and 1×PCR buffer (Fermentas, Canada) was used for 
each sample. The PCR reactions were conducted in 
a thermocycler (Bio-rad, USA) with the following 
program: 94˚C for 5 minutes, 35 cycles at 94˚C for 45 
seconds, 55˚C for 45 seconds, 72˚C for 45 seconds, 
and a final extension at 74˚C for 10 minutes. Ten µg 
of the PCR product were separated, run on a 1.5% 
agarose gel, and stained with SYBR safe.
Table 1: Primers and expected length of products
Primer Sequence (5΄-3΄) Length 
(bp)
β-actin F: CTCTGTGTGGATTGGTGGCT
R: CGCAGCTCAGTAACAGTCCG
219
Melatonin 
Receptor1
(MT1)
F: CGGACAGCAAACCCAAACT
R: AACTAGCCACGAAGAGCCAC
152
MT2 F: TGACCTGTTACTGAATGTTGCC
R: GAACTGCGATTTCTGGGTTAC
199
BAX F: AACAACATGGAGCTGCAGAGG
R: GAAGTTGCCGTCTGCAAACAT
304
BCL-2 F: TGACTTCTCTCGTCGCTACC
R: CACAATCCTCCCCCAGTTCA
116
Osteocalcin F: AGGACCCTCTCTCTGCTAC
R: AACGGTGGTGCCATAGATGC
138
Apoptosis detection
The cells were grown in a 96-well plate and pretreated 
with 5 µM melatonin for 24 hours. Following the 
treatment, the cells were rinsed with PBS and fixed in 4% 
paraformaldehyde. The endogenous peroxidase activity 
was blocked by methanol followed by cell permeabilization 
with a cocktail of 1 g/L TritonX-100 in 0.1% sodium 
citrate. TUNEL reaction solution and Converter-POD 
were added to the cells according to the kit manual. The 
reaction was developed by 3, 3′-diaminobenzidine (DAB) 
and cell apoptosis was observed under light microscope 
(Ziess Germany) with 400 magnification.
Osteogenesis analysis using alizarin red concentration
To investigate the effects of melatonin on osteogenic 
differentiation potentials of the stem cells before and after 
pretreatment with melatonin, osteogenic differentiation 
was induced and after 21 days osteogenesis was analyzed 
using alizarin red. 
Statistical analysis
Our data was analyzed by two-way ANOVA, followed 
by Bonferroni post hoc test, and was presented as the 
mean ± SD. P<0.05 was considered as significant. All 
experiments were performed in at least triplicates.
Results
BMSCs were expanded easily and had multi-lineage 
differentiation potentials
The isolated BMSCs were adhered to the culture dish 
after 24-48 hours and their primary round form changed 
to a more spindle-like shape (Fig.1A). Deposition of 
calcium and alizarin red staining after 21 days of culture 
showed that the cells differentiated into osteoblasts  in 
differentiation medium  (Fig.1B). Similarly, after 5 
days in culture, cells that were plated in adipogenic 
differentiation medium successfully stained with oil-
red-O, demonstrating adipogenic potentials of the 
harvested cells prior to tratment (Fig.1C).
Isolation, expansion and multi-lineage differentiation 
potential of ADSCs
The isolated cells from rat adipose tissue adhered to 
tissue culture flasks within 48-72 hours after adhesion 
they formed spindle-like shapes (Fig.1D). Since the 
first passage, every 2-3 days the cells grew to become 
confluent in the flasks and needed to be passaged. The 
isolated cells deposited calcium and stained red (Fig.1C) 
after 21 days in osteogenic differentiation medium. The 
cells in adipogenic differentiation medium also confirmed 
adipogenesis by staining with oil-red-O staining. These 
cells were cultured for 5 days in the differentiation 
medium (Fig.1D).
Melatonin increased cell viability independently from 
the cell origin
MTT assay analysis showed that pretreatment of the 
cells with melatonin increased their viability in both 
BMSCs and ADSCs after being cultured in osteogenesis 
medium. Although, there were significant differences 
between the melatonin groups and the controls, no 
differences were found in cell viability between BMSCs 
and ADSCs. It seems that melatonin increase cell 
proliferation independently from the source or origin of 
the cells (Fig.2).
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Fig.1: The morphology of undifferentiated and differentiated BMSCs and ADSCs. A, D. Undifferentiated BMSCs and ADSCs, display a flattened fibroblast-like 
morphology under phase-contrast microscopy. Alizarin red staining of the B. BMSCs and E. ADSCs after culturing for 21 days in osteogenic differentiation 
medium. Oil-red-O staining of the C. BMSCs and F. ADSCs after culturing for 5 days in adipogenic differentiation medium (scale bar: 200 µm). 
BMSCs; Bone marrow mesenchymal stem cells and ADSCs; Adipose tissue-derived mesenchymal stem cells.
Fig.2: Viability of the cells pretreated with melatonin in BMSCs and 
ADSCs after culturing them in osteogenic medium. 
a; P<0.001, compare to Cont/BMSC (control BMSCs: BMSCs were 
cultured without differentiation medium), b; P<0.05, compare to 
BMSC, c; P<0.001, compare to Cont/ADSC (control ADSC: ADSC were 
cultured without differentiation medium), d; P<0.05, compare to ADSC, 
e; P<0.05, compare to MT-BMSC, BMSCs; Bone marrow mesenchymal 
stem cells, ADSCs; Adipose tissue-derived mesenchymal stem cells, 
and MT; Melatonin.
Gene expression profile changes after melatonin 
preconditioning in BMSCs and ADSCs
Gene expression profile of MSCs after melatonin 
pretreatment for BAX, BCL2, MT1, MT2 and 
osteocalcin were analyzed using RT-PCR. Our results 
indicated that melatonin decreased BAX expression, 
as a pro-apoptotic gene, significantly in BMSCs and 
ADSCs after 24 hours of pretreatment, but it was less 
significant in ADSCs (Fig.3A, B). Also, melatonin 
upregulated expression of the anti-apoptotic gene 
BCL2 significantly in both cell types. However, the 
expression was slightly higher in ADSCs (Fig.3C, 
D). The expression of melatonin receptors (MT1 and 
MT2) was detected in both of BMSCs and ADSCs. It 
was found that after melatonin preconditioning, both 
MT1 and MT2 were upregulated significantly in the 
two cell types. However, their increase was higher 
in BMSCs than in ADSCs but was not significant 
(P>0.05, Fig.3E-H).
After 3 weeks our findings indicated that pretreatment 
with melatonin increased the expression of osteoblast 
cell marker, osteocalcin, in both BMSCs and ADSCs. 
Although the expression of osteocalcin in BMSCs before 
and after preconditioning with melatonin was higher 
than that in ADSCs, as a result of melatonin treatment 
osteocalcin expression increased more significantly in 
ADSCs compared to BMSCs (Fig.3I, J).
Melatonin exerts its protective properties through 
suppression of apoptosis
Cell death detection was performed to know whether 
melatonin might decrease apoptosis in BMSCs and 
ADSCs. Our findings showed that melatonin reduced 
apoptosis in the BMSCs and ADSCs significantly after 
osteogenesis, but its efficiency was more in ADSCs 
compared to BMSCs (Fig.4).
A
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Fig.3: The graph and Electrophotograms of RT-PCR product. A, B. BAX expression of BMSCs, MT-BMSCs, ADSC, MT-ADSC, C, D. BCL2 expression of BMSCs, MT-BMSCs, ADSC, MT-ADSC 
(a; Compare to BMSC, b; Compare to ADSC, c; Compare to MT-BMSC), F, H. Gene expression of MT1 and MT2, E, G. The graph demonstrates MT1 (a; Compare to BMSC, b; Compare 
to MT-ADSC, c; Compare to MT-BMSC), MT2 (a; Compare to BMSC, b; Compare to ADSC, c; Compare to MT-BMSC) of BMSCs, MT-BMSCs, ADSC, MT-ADSC presents osteocalcin 
expression level extracted from BMSCs, MT-BMSCs, ADSC, MT-ADSC (a; Compare to BMSC, b; Compare to ADSC, c; Compare to MT-BMSC). Negative control of RT-PCR: (H
2
O) (Lane 
1), BMSC (Lane 2), MT-BMSC (Lane 3), ADSC (Lane 4), MT-ADSC (Lane 5) (P<0.05).
RT-PCR; Reverse transcriptase-polymerase chain reaction, BMSCs; Bone marrow mesenchymal stem cells, ADSCs; Adipose tissue-derived mesenchymal stem cells, and MT; Melatonin.
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Fig.4: Cell death was detected by TUNEL assay.  The apoptotic cells presented their morphology by round shape and brown nuclei. A. Control, 
B. Apoptotic cells before pretreatment with melatonin, C. Apoptotic BMSCs after pretreatment with melatonin, D. Control, E. The cells before 
pretreatment with melatonin, F. ADSCs after pretreatment with melatonin, and G. The graph shows apoptotic cell numbers before and after 
pretreatment with melatonin. Melatonin decreased apoptotic cells in ADSCs more than in MSCs (scale bar: 200 µm). 
a; Compare to Cont/BMSC, b; Compare to BMSC, c; Compare to Cont/ADSC, d; Compare to MT-ADSC, e; Compare to MT-BMSC (P<0.05), BMSCs; 
Bone marrow mesenchymal stem cells, ADSCs; Adipose tissue-derived mesenchymal stem cells, and  MT; Melatonin.
Osteogenic differentiation potentials of melatonin is 
dependent on the source of MSCs
Before and after preconditioning with melatonin, 
both BMSCs and ADSCs were induced for osteogenic 
differentiation. After 21 days, the cells were stained 
with alizarin red and quantitative analysis of alizarin 
red concentration was performed. As showed in 
Figure 5, pretreatment with melatonin increased 
alizarin red concentration significantly in both 
BMSCs and ADSCs (P<0.05). The increase of alizarin 
red concentration in ADSCs after preconditioning 
with melatonin was significantly higher than that in 
BMSCs (P<0.05). 
Melatonin Effects on BMCS and ADSC Survival and Differentiation
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Fig.5: Alizarin red staining for mineral deposition after osteogenic differentiation before and after preconditioning with melatonin. A. Control/BMSCs, B. BMSCs, 
C. MT-BMSCs, D. Control/ADSCs, E. ADSCs, F. MT-ADSCs after days, and G. The graph shows Alizarin Red concentration in BMSCs and ADSCs before and after 
preconditioning with melatonin. The concentration of alizarin red increased significantly after preconditioning in both cell types, but, more significantly in BMSCs. 
BMSCs; Bone marrow mesenchymal stem cells, ADSCs; Adipose tissue-derived mesenchymal stem cells, a; Compare to Cont/BMSCs, b; Compare to BMSCs, c; 
Compare to MT-ADSCs, d; Compare to cont/ADSCs, and e; Compare to ADSCs (P<0.05). 
Discussion
The present study was designed to analyze and compare 
preconditioning efficacy of melatonin in BMSCs and 
ADSCs as two important sources of stem cells for cell 
therapy and regenerative medicine. 
Our findings are in agreement with previous studies, 
which demonstrated that melatonin is a potent 
preconditioning agent for BMSCs and ADSCs (15). 
Based on our findings, melatonin increases cell viability 
and inhibits apoptosis, with a higher efficacy in ADSCs 
compared to BMSCs. Preconditioning with melatonin 
increases cell viability approximately equally in both 
cell types, but it suppresses apoptosis in ADSCs more 
significantly than in BMSCs. Also down-regulation 
of BAX and up-regulation of BCL2 in ADSCs are 
significantly more than those in BMSCs. The expression 
of MT1 and MT2 in BMSCs is significantly higher than 
that in ADSCs. These findings confirm the previous 
findings, in which melatonin represented its protective 
effects via both receptor-mediated and receptor-
independent mechanisms (11).
Rafat et al.
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It is clear that, with the induction of specific melatonin 
receptors, the antioxidant enzymes, such as catalase and 
superoxide dismutase-1, are overexpressed, therefore 
increasing the MSC resistance to hydrogen peroxide-
dependent apoptosis (15).
It has been documented that melatonin has receptor-
mediated protective potentials, which result in improved 
MSC survival (15, 16) and reduced apoptosis (11, 15). 
It is reported that pretreatment with melatonin has cyto-
protective potentials against H
2
O
2
 toxicity and increases 
MSC viability through an increase in antioxidants capacity, 
a decline in apoptosis and secretion of inflammatory 
cytokines (17).
Han and his colleagues have shown that melatonin 
can increase the therapeutic efficiency of MSCs through 
activation of antioxidant induction pathways, such as 
silent information regulator 1 (SIRT1), and upregulation 
of anti-apoptotic genes (18).
In another study, melatonin protected ADSCs from ROS 
and improved their therapeutic efficiency in a rat model 
of myocardial infarction (19). Also, ex vivo pretreatment 
with melatonin enhanced the viability, proangiogenic/
mitogenic activity and efficiency of transplanted MSCs in 
ischemic kidneys.
Our study demonstrates that melatonin increases 
osteogenic differentiation potentials of BMSCs and 
ADSCs, while efficacy of melatonin in osteogenic 
differentiation of ADSCs is higher than that in BMSCs. In 
concurrent with our findings, other studies have confirmed 
the capacity of melatonin in improving bone growth 
through development in osteoblast cell differentiation and 
functional competence (20). 
It is also demonstrated in other studies that melatonin 
could regulate the osteogenic differentiation of MSCs 
through interactions with molecules suc  as bone-
secreted protein (BSP), alkaline phosphatases (ALP) and 
osteopontin (21).  
Melatonin preconditioning could enhance ADSC 
and BMSC viability, and on the other hand, decline the 
number of apoptotic cells. It also improves osteogenic 
differentiation of these cells. Since there are promising 
reports about increasing cell therapy outcomes using 
melatonin (15, 16), further studies should be conducted 
on comparison of different cell types in response to 
melatonin administration. In addition, the optimal dose 
and time of melatonin application with regards to the 
sources of MSCs should be investigated. 
Conclusion
Our study demonstrated that melatonin preconditioning 
promotes BMSC and ADSC survival, reduces apoptosis 
and has positive effects on osteogenic differentiation 
potentials in vitro. Also these results showed that 
preconditioning affects melatonin expression in ADSCs 
in a higher level than that in BMSCs. This result can be 
used in establishing a proper preconditioning protocol for 
specific MSCs used in clinical applications, especially for 
bone formation.
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